immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. It operates in the Commercial and Research segments. The Commercial segment involves the sales, marketing, laboratory, and support to run the commercial businesses worldwide. The Research segment engages in the research and development of diagnostic and prognostic products for human cancer. The company was founded on February 27, 2001 and is headquartered in Dunedin, New Zealand.

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products.Veridex’s products will significantly benefit patients through earlier disease detection, and will enable personalized strategies to improve patient management and outcomes.

Zalicus Inc., formerly CombinatoRx, Incorporated, is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. On March 1, 2010, the United States Food and Drug Administration, (FDA), approved the New Drug Application (NDA) for Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. On December 21, 2009, the Company merged with Neuromed Pharmaceuticals, Inc. and its subsidiaries.

The Texas A&M University System creates a seamless pathway for students to earn an associate and bachelor’s degree in related fields

Fujirebio Diagnostics AB develops and manufactures immunological reagents. It focuses on the development of monoclonal antibodies which fight against biochemical markers of diseases. The firm distributes products to the international biotech and diagnostic industries. The company is headquartered in Gothenburg, Sweden.

The Feinstein Institutes for Medical Research comprise the research arm of Northwell Health. Feinstein is home to 50 research labs, 2,500 clinical research studies, and 4,000 professional and support staff. Feinstein researchers have made breakthroughs in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine, among others, and continue work in those and other areas. Feinstein is the laboratory and faculty home of the Elmezzi Graduate School of Molecular Medicine. Additionally, students without an MD degree may earn a PhD in molecular medicine via the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, as part of the medical school's MD/PhD or PhD programs.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Janssen Diagnostics LLC, a subsidiary of Johnson & Johnson, is an American company located in Raritan, NJ. The firm designs and manufacture special machinery for the pharmaceutical industry.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company. Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada.

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Nanjing Tianzhixin Technology Co., Ltd., established on 2019-09-30, Business scope includes research and development of environmental protection technology,technology transfer,technical consulting;network technology,Computer software technology research and development,technology transfer;Computer hardware and software and accessories,Network equipment,Communication equipment sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.